Below are the estimated distribution timelines, supply deals announced to date, and ongoing clinical trials in the region. Pfizer Inc together with its partners BioNTech SE, Moderna Inc and AstraZeneca.
Pilot data this month shows that their experimental vaccines are effective in preventing disease. If regulators approve any of the vaccines in the coming weeks, the companies say distribution could begin almost immediately with governments around the world.
But many Asian countries do not expect to receive large sums initially, and here are the estimated distribution schedules, supply deals announced so far, and clinical trials underway in the region. Australia has agreed to purchase 135 million doses: 34 million from AstraZeneca, 40 million from Novavax Inc, 10 million from Pfizer, and 51 million from CSL Ltd. It expects to deliver 3.8 million doses of the AstraZeneca vaccine in January and February of next year. China China has not announced supply deals with Western pharmaceutical companies, which have partnered with private companies instead.
AstraZeneca vaccine may be approved in China by mid-2021 and its Chinese partner Shenzhen Kangtai Biological Products plans to have an annual production capacity of at least 100 million doses of vaccine by the end of 2020. For the Pfizer / BioNTech vaccine, a unit of Shanghai Fosun Pharmaceutical Group is planning To try the second stage.
Tibet Rhodiola Pharmaceutical Holding is bringing Sputnik V of the Russian vaccine candidate and plans early and medium trials of the vaccine in China. China has also approved three candidate vaccines developed by the state-owned Sinovac and Sinopharm for its emergency use program, and Sinopharm hopes its candidates will receive conditional approval for public use within this year.
Japan Japan has deals for 120 million doses of Pfizer / BioNTech in the first half of next year, 120 million doses of AstraZeneca, the first 30 million of which will be shipped by March 2021, and 250 million doses of Novavax.
It is also in talks with Johnson & Johnson and has an agreement with Shionogi & Co. Experts said vaccine makers will need to conduct at least Phase 1-2 trials in Japan before approval can be obtained. South Korea aims to secure vaccines for 10 million people from COVAX and 20 million people from separate deals with drugmakers by the end of this year.
It has a "selective purchase" arrangement with COVAX that allows it to select vaccines from specific vaccine manufacturers. The timing of purchase and the quantity depend on the production schedule for those vaccines, according to health officials. Vaccination will likely begin in the second quarter of next year to allow more time to notice potential side effects.
India The head of India's Serum Institute, which makes the AstraZeneca vaccine, said on November 23 that the positive result of the late trial would allow the candidate to obtain emergency use permission by the end of the year, before receiving approval for its full rollout by the end of the year. February or March next year.
India also expects to launch a government-backed vaccine as early as February, while a late-stage trial is underway with Sputnik V. Taiwan Taiwan aims to initially secure around 15 million doses, either via the COVAX scheme or by direct purchase from vaccine manufacturers, and may purchase 15 million additional doses. The government said it hoped to start vaccination in the first quarter of next year.